Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

8208960

Reference Type

Journal Article

Title

Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial

Author(s)

Beiraghdar, F; Panahi, Y; Einollahi, B; Nemati, E; Ghadiani, MH; Sahebkar, A; Maghsoudi, N; Marzony, ET; ,

Year

2012

Is Peer Reviewed?

Yes

Journal

Clinical Laboratory
ISSN: 1433-6510

Publisher

CLIN LAB PUBL

Location

HEIDELBERG

Page Numbers

737-745

Language

English

PMID

22997974

DOI

10.7754/Clin.Lab.2011.110812

Web of Science Id

WOS:000308385700014

URL

https://www.clin-lab-publications.com/article/939
Exit

Abstract

Recombinant human erythropoietin (rHuEPO) is the cornerstone therapy for anemia associated with chronic kidney disease. However, not all patients with renal anemia receive sufficient doses of rHuEPO due to its high cost. The present trial aimed to evaluate the efficacy of Epolyrec, a biogeneric rHuEPO, in the management of renal anemia in patients on hemodialysis.